

Docket No.: 22116-00002-US2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED  
CENTRAL FAX CENTER

In re Patent Application of:  
Mark R. Burns et al.

JAN 11 2006

Application No.: 10/810,649

Confirmation No.: 3790

Filed: March 29, 2004

Art Unit: 1625

For: POLYAMINE ANALOGS THAT ACTIVATE  
ANTIZYME FRAMESHIFTING

Examiner: DESAI, Rita J.

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The undersigned is attorney of record for the assignee of the above-identified application. MediQuest Therapeutics, Inc certifies that MediQuest Therapeutics, Inc owns the entire right, title and interest in the above identified patent application, as evidenced by the attached assignment, said assignment to MediQuest Therapeutics, Inc. having been recorded in the U.S. Patent and Trademark Office on June 18, 2004 at Reel 014707, Frame(s) 0891.

The owner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of U.S. Patent No. 6,914,079. The owner hereby agrees that any patent that is granted on the above-identified application shall be enforceable only for and during such period that it and the above listed patent application are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assignees.

01/12/2006 YPOLITE1 00000034 220185 10810649

01 FC:1814 130.00 DA


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the US Patent 6,914,079 as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminate prior to the expiration of its full statutory term.

Please charge our Deposit Account No. 22-0185 in the amount of \$130.00 covering the fee set forth in 37 CFR 1.20(d). The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22116-00002-US-2. A duplicate copy of this paper is enclosed.

Dated:

1/11/06

Respectfully submitted,

By  
Burton A. Amernick

Registration No.: 24,852

(Attorney for the assignee, MediQuest  
Therapeutics, Inc owner of the entire right,  
title and interest to this application)

CONNOLLY BOVE LODGE &amp; HUTZ,

1990 M Street, N.W., Suite 800

Washington, DC 20036-3425

(202) 331-7111

(202) 293-6229 (Fax)

Attorneys for Applicant